GlassScriptPhysician profile
James R Commers
NPI 1871687681
$1,410.45
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $88.68 · 2021: $410 · 2022: $491.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $189.02 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $166.63 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $118.54 | 2019-2022 | |
| Janssen Biotech, INC. | $104.46 | 2019-2022 | |
| Genzyme Corporation | $98.65 | 2019-2022 | |
| Lilly USA, LLC | $93.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $72.41 | 2021-2022 | |
| Amgen INC. | $55.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.19 | 2019-2022 | |
| Pfizer INC. | $42.99 | 2019-2022 | |
| Genentech USA, INC. | $39.45 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $33.19 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $32.57 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $28.31 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2019 | |
| Agios Pharmaceuticals, INC. | $26.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $26.62 | 2021-2022 | |
| Blueprint Medicines Corporation | $23.09 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.63 | 2019 | |
| Glaxosmithkline, LLC. | $20.26 | 2021 | |
| Astellas Pharma US INC | $19.27 | 2022 | |
| Karyopharm Therapeutics INC. | $17.00 | 2021 | |
| Incyte Corporation | $16.29 | 2021 | |
| Morphosys, US INC. | $13.22 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Abbvie INC. | $11.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Commers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.